BioCentury
ARTICLE | Company News

Genomics England partners with industry on 100,000 Genomes Project

March 27, 2015 12:50 AM UTC

Genomics England Ltd. (London, U.K.) said 10 pharma and biotech companies will form the Genomics Expert Network for Enterprises (GENE) Consortium. The group will collaborate with and analyze data from the U.K.'s 100,000 Genomes Project, which aims to sequence and study the genomes of 100,000 NHS England patients with a focus on rare diseases and cancers including breast, prostate, ovarian, hematological, pancreatic and colorectal.

Consortium members include AbbVie Inc. (NYSE:ABBV), AstraZeneca plc (LSE:AZN; NYSE:AZN), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Biogen (NASDAQ:BIIB), Dimension Therapeutics Inc. (Cambridge, Mass.), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Helomics Corp. (Pittsburgh, Pa.); Roche (SIX:ROG; OTCQX:RHHBY) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Genomics England said UCB Group (Euronext:UCB) also will be a member, but has not yet signed a contract. Genomics England plans to seek more partners. ...